Hepatect Cp 50 I.E./Ml Infusion
Hepatitis B Virus Infection
Explore 22 assets in Hepatitis B Virus Infection →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Medical University of Graz
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05293158CT.gov Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis B Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatect Cp 50 I.E./Ml Infusion (this asset) | Medical University of Graz | N/A | D · 30 |
| Entecavir | Sun Yat-sen University | P4 | BBB |
| Lamivudine | Fudan University | P4 | BBB |
| Tenofovir | Ruijin Hospital | P4 | BB |
| Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester | West China Hospital | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Tenofovir Alafenamide | Sun Yat-sen University | P4 | BB |
| Besifovir Dipivoxil | IlDong Pharmaceutical Co Ltd | P4 | BB |
+34 more in the Hepatitis B Virus Infection cohort
Other indications for Hepatect Cp 50 I.E./Ml Infusion
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | N/A | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hepatect Cp 50 I.E./Ml Infusion in Hepatitis B Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hepatect-cp-50-ieml-infusion-hepatitis-b-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →